

# CBI's Cardiovascular Disease Drug Development Summit

OCTOBER 29-30, 2008  
MARRIOTT BETHESDA  
BETHESDA, MD

Pharmaceutical  
**BUSINESS**  
Review

Search this site:

GO

[Advanced Search](#)

## HOME

Latest News

Comment & Opinion

Industry Metrics

Newsletter Sign-up

## ANALYSIS CENTERS

Drug Delivery

Epidemiology

Generics

Medical Devices

Strategic Issues

Therapeutic Areas

## RESOURCES

Company Data

Dining Club

Events & Webinars

White Papers

## INTELLIGENCE STORE

Latest Research

Browse by Industry

Best Selling Reports

Industry Profiles

Customer Service

## ABOUT US

Meet the Team

RSS Feeds

Advertise with us

Contact us

Privacy Policy

## HemCon Medical completes fungal nail infection study

15th October 2008

By Staff Writer

**HemCon Medical Technologies has completed two independent studies on its topical treatment of onychomycosis, a common fungal nail infection.**

The studies were conducted with a formulation based on HemCon's newest proprietary platform technology that provides a controlled release broad spectrum antifungal and antibacterial agent to fight infection.

Independent testing of HemCon's topical formulation for the treatment of onychomycosis was analyzed by MedPharm using its TurChub test system. This system tests the penetration of human nails by the test substance and subsequent killing of the fungal infection underneath.

HemCon's formulation was evaluated against two onychomycosis treatments. The HemCon formulation successfully penetrated the nail and killed the infection to a significantly greater extent than the other treatments. In a second, human-based study, safety results indicated that no skin irritation was seen from the topical formulations of HemCon's onychomycosis treatment.

John Morgan, CEO of HemCon, said: "These studies confirm the promise of our new treatment, which has the potential to offer effective relief for the 40 million Americans afflicted with fungal nail infections. As HemCon continues to pioneer new products that promote safe, effective healing, our solutions will also positively impact high demand markets like fungal treatment. These impressive test results will allow us to further develop products based on this new platform and offer them on a global scale."

### YOUR OPINION...

[Comment on this Article](#)

### NEWSLETTER SUBSCRIPTIONS

Sign up to our weekly newsletters for the latest industry news & comment.

- |   |  |
|---|--|
| <input checked="" type="checkbox"/> Business Digest | <input type="checkbox"/> Drug Delivery News                |
| <input type="checkbox"/> Epidemiology News          | <input type="checkbox"/> Generics News                     |
| <input type="checkbox"/> Medical Devices News       | <input checked="" type="checkbox"/> Pharmaceuticals Digest |
| <input type="checkbox"/> Strategic Issues News      | <input type="checkbox"/> Therapeutic Areas News            |

Email Address

SUBSCRIBE

-  Printer Friendly
-  Email Article
-  Your Comment
-  Post to del.icio.us
-  Digg this story



### BUSINESS REVIEW SITES:

Food | Drinks | Pharma | Tech  
Energy | Banking | Insurance | Auto

©2008 Progressive Media Group